STING1 and cancer: Huvila et al. (2021) reported that STING expressed highly in low grade serous ovarian carcinoma and serous borderline tumors, heterogeneously expressed in high-grade serous and endometrioid carcinomas, but with low levels in clear cell and mucinous carcinomas. Such expression pattern of STING across OC subtypes may suggest differed functions of STING in different cellular origins of OC tumorigenesis. Indeed, cGAS-STING signaling pathway has been revealed as a “double edged sword” in various cancer types, including OC (Du et al., 2022).